1. Home
  2. LYRA vs CMLS Comparison

LYRA vs CMLS Comparison

Compare LYRA & CMLS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • LYRA
  • CMLS
  • Stock Information
  • Founded
  • LYRA 2005
  • CMLS 2002
  • Country
  • LYRA United States
  • CMLS United States
  • Employees
  • LYRA N/A
  • CMLS N/A
  • Industry
  • LYRA Medical/Dental Instruments
  • CMLS Broadcasting
  • Sector
  • LYRA Health Care
  • CMLS Consumer Discretionary
  • Exchange
  • LYRA Nasdaq
  • CMLS Nasdaq
  • Market Cap
  • LYRA 18.0M
  • CMLS 21.5M
  • IPO Year
  • LYRA 2020
  • CMLS 1998
  • Fundamental
  • Price
  • LYRA $0.17
  • CMLS $0.71
  • Analyst Decision
  • LYRA Buy
  • CMLS Hold
  • Analyst Count
  • LYRA 5
  • CMLS 2
  • Target Price
  • LYRA $4.50
  • CMLS N/A
  • AVG Volume (30 Days)
  • LYRA 2.2M
  • CMLS 63.9K
  • Earning Date
  • LYRA 11-12-2024
  • CMLS 11-01-2024
  • Dividend Yield
  • LYRA N/A
  • CMLS N/A
  • EPS Growth
  • LYRA N/A
  • CMLS N/A
  • EPS
  • LYRA N/A
  • CMLS N/A
  • Revenue
  • LYRA $1,471,000.00
  • CMLS $829,801,000.00
  • Revenue This Year
  • LYRA $13.99
  • CMLS N/A
  • Revenue Next Year
  • LYRA N/A
  • CMLS N/A
  • P/E Ratio
  • LYRA N/A
  • CMLS N/A
  • Revenue Growth
  • LYRA 3.37
  • CMLS N/A
  • 52 Week Low
  • LYRA $0.17
  • CMLS $0.70
  • 52 Week High
  • LYRA $6.79
  • CMLS $5.51
  • Technical
  • Relative Strength Index (RSI)
  • LYRA 30.70
  • CMLS 18.95
  • Support Level
  • LYRA $0.26
  • CMLS $0.86
  • Resistance Level
  • LYRA $0.28
  • CMLS $0.76
  • Average True Range (ATR)
  • LYRA 0.02
  • CMLS 0.08
  • MACD
  • LYRA -0.01
  • CMLS -0.02
  • Stochastic Oscillator
  • LYRA 1.69
  • CMLS 1.96

About LYRA Lyra Therapeutics Inc.

Lyra Therapeutics Inc is a clinical-stage therapeutics company focused on the development and commercialization of novel integrated drug and delivery solutions for the localized treatment of patients with ear, nose, and throat diseases. The Company's operations and manages its business as a single operating segment which is the business of developing targeted medicines to address ears, nose, and throat, or ENT diseases. Its initial product candidates, LYR-210 and LYR-220, are bioresorbable polymeric matrices designed to be administered in a brief, non-invasive, in-office procedure and intended to deliver up to six months of continuous drug therapy to the sinonasal passages for the treatment of chronic rhinosinusitis, or CRS.

About CMLS Cumulus Media Inc.

Cumulus Media Inc is an audio-first media company delivering content to over a quarter billion people every month wherever and whenever required. It is a radio broadcasting company combining high-quality local programming with iconic, nationally syndicated media, sports, and entertainment brands to deliver premium content choices to its customers and radio stations affiliated with Westwood One network and numerous digital channels. The company's revenue is derived mainly from the sale of local, regional, and national advertising which is broadcast on its radio stations.

Share on Social Networks: